Want to see KR:005500 full AI Analyst Report?
Samjin Pharmaceutical Co., Ltd. (005500) Income Statement
Samjin Pharmaceutical Co., Ltd. Income Statement
Last quarter (Q2 2026), Samjin Pharmaceutical Co., Ltd.'s total revenue was $79.63B, an increase of 6.73% from the same quarter last year. In Q2, Samjin Pharmaceutical Co., Ltd.'s net income was $6.10B. See Samjin Pharmaceutical Co., Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 309.13B | $ 308.35B | $ 292.13B | $ 274.03B | $ 250.07B | |
| $ 153.03B | $ 128.97B | $ 145.89B | $ 117.73B | $ 117.83B | |
| $ 128.35B | $ 97.33B | $ 126.39B | $ 94.55B | $ 83.92B | |
| Depreciation and Amortization | $ 19.82B | $ 17.40B | $ 16.61B | $ 9.82B | $ 7.36B |
| $ 44.50B | $ 65.92B | $ 36.60B | $ 36.81B | $ 42.41B | |
| $ 24.68B | $ 31.64B | $ 19.50B | $ 23.18B | $ 33.91B | |
| $ -2.59B | $ 12.00B | $ -4.89B | $ 2.04B | $ 999.81M | |
| $ 22.10B | $ 43.64B | $ 15.60B | $ 25.23B | $ 34.91B | |
| $ 24.17B | $ 39.23B | $ 18.91B | $ 21.89B | $ 28.40B | |
| Per Share Metrics | |||||
| Basic EPS | $ 1962.68 | $ 3110.66 | $ 1460.00 | $ 1727.82 | $ 2308.75 |
| Diluted EPS | $ 1962.68 | $ 3110.66 | $ 1459.66 | $ 1727.82 | $ 2308.75 |
| Weighted Average Shares Outstanding | 12.25M | 12.61M | 12.95M | 12.67M | 12.30M |
| Weighted Average Shares Outstanding (Diluted) | 12.25M | 12.61M | 12.95M | 12.67M | 12.30M |
Currency in KRW
